Hope on the Horizon: Advances in Pancreatic Cancer

In this presentation, Dr. Brandon G. Smaglo, Assistant Professor, Department of Medicine, Hematology-Oncology, Baylor College of Medicine, discusses the current state-of-the-art in pancreatic cancer care. Pancreatic cancer is the third leading cause of cancer-related mortality in the United States.  Pancreatic cancer that is resectable is associated with favorable outcomes. Outcomes for locally advanced, unresectable pancreatic cancer are poor. Determining resectability requires multidisciplinary case review as well as dedicated imaging of the primary tumor. 

Dr. Benjamin Musher, Associate Professor, Department of Medicine, discusses unmet needs and novel treatment options in development for pancreatic cancer. Drs. Musher and Smaglo focus on the novel therapeutics being investigated in clinical trials at BCM’s Dan L. Duncan Comprehensive Cancer Center, including cancer stem cell inhibitors, immune checkpoint inhibitors, and multi-tumor-associated antigen cytotoxic T-lymphocyte therapy. 

Target Audience

This CME/CE activity is designed to meet the educational needs of physicians, residents, fellows, and community providers.

Faculty and trainees within the Department of Medicine who are involved in the care of patients need to be regularly updated with the recent advances and guidelines in the fields of internal medicine and quality improvement to increase clinical knowledge, and to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Provide a brief overview of the staging and treatment of pancreatic cancer.

  • Implement rigorous laboratory and clinical investigation to support efforts to improve outcomes for patients with the most refractory types of cancer.

  • Discuss novel therapeutics for pancreatic cancer, focusing on trials being conducted at Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/01/2019
Course expires: 
08/31/2021
Rating: 
0

Richard J. Hamill, M.D., Planning Committee Member 
Professor
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Erica Lescinskas, M.D., Planning Committee Member
Assistant Professor
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Zaven Sargsyan, M.D., Planning Committee Member
Assistant Professor
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Chirayu Shah, M.D., M.Ed., Planning Committee Member
Associate Professor
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Stephanie Sherman, M.D., Planning Committee Member
Assistant Professor
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Jefferson Triozzi, M.D., Planning Committee Member
Internal Medicine Resident
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or register to take this course.